Several studies have shown that dual treatment with selective inhibitors of PI3K/Akt and BRAF is associated with a synergistic tumor growth inhibition in mutated CRC cell lines presenting primary resistance to a BRAF inhibitor [36, 37]. The gene discussed is BRAF; the disease is neoplasm.